For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Sc ...

Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosisGSK to participate in Series C Extension with equity investmentSeries C financing round extended overall by CHF 12.3 million to CHF 44.9 million BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by m ...

Nick Stone - Head of Investor Relations Emma Walmsley - Chief Executive Officer Luke Miels - Chief Commercial Officer Deborah Waterhouse - Chief Executive Officer, ViiV Healthcare Julie Brown - Chief Financial Officer Tony Wood - Chief Scientific Officer Hello everyone. Welcome to todayâs call and webcast. The presentation was sent to our distribution list by email, and you can also find it on gsk.com. Emma Walmsley For the full-year, we are upgrading our guidance and looking forward to delivering another y ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number 001-15170 GSK plc (Translation of registrant's name into English) 980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40 ...

GSK plc (GSK) reported core earnings of $1.09 per American depositary share (“ADS”) in first- quarter 2024, beating the Zacks Consensus Estimate of 94 cents. Core earnings rose 16% year over year on a reported basis and 28% at a constant exchange rate (CER).Quarterly revenues increased 6% on a reported basis and 10% at CER to $9.34 billion (£7.36 billion), beating the Zacks Consensus Estimate of $8.98 billion. The upside can be attributed to rising HIV and vaccine product sales, which was partially offset b ...

GSK (GSK) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $0.90 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15.96%. A quarter ago, it was expected that this drug developer would post earnings of $0.76 per share when it actually produced earnings of $0.72, delivering a surprise of -5.26%.Over the last four quarters, the company has su ...

Wall Street expects a year-over-year increase in earnings on higher revenues when GSK (GSK) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 1. On the other ha ...

GSK (GSK) closed the most recent trading day at $39.75, moving +1.22% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.88%. Elsewhere, the Dow saw an upswing of 0.56%, while the tech-heavy Nasdaq depreciated by 2.05%.Heading into today, shares of the drug developer had lost 7.32% over the past month, lagging the Medical sector's loss of 6.4% and the S&P 500's loss of 2.57% in that time.The investment community will be closely monitoring the performance of GSK ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scores?The ...

GSK plc (GSK) announced that the FDA has accepted its biologics license application (BLA) seeking approval of its 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY. The FDA has granted a standard review to the BLA and is expected to give its decision on Feb 14, 2025.The MenABCWY vaccine candidate combines the antigenic components of GSK’s two popular licensed meningococcal vaccines, Bexsero (MenB) and Menveo (MenACWY). The MenABCWY combination targets the five serogroups of the bacteria Neisseria menin ...